20 Prostate Cancer

Prostate Cancer

19

THE GEC ESTRO HANDBOOK OF BRACHYTHERAPY | Part II: Clinical Practice Version 1 - 01/12/2014

28. Pieters BR, van der Grient JN, Blank LE, Koedooder K, Hulshof MC, de Reijke TM Minimal displacement of novel self-anchoring catheters suitable for tem- porary prostate implants. Radiother Oncol. 2006 Jul;80(1):69-72 29. Papagiannis P, Sakelliou L, Georgiou E, Hourdakis CJ, Baltas D Comparison of radiation shielding requirements for HDR brachytherapy using 169Yb and 192Ir sources Med Phys. 2006 Jul;33(7):2541-7 30. Baltas D, Sakelliou L, Zamboglou N. The Physics of Modern Brachytherapy for Oncology. Taylor & Francis, New York London, 2007. 31. Salembier C, Lavagnini P, Nickers P, Mangili P, Rijnders A, Polo A, Venselaar J, Hoskin P. Tumour and target volumes in permanent prostate Brachythera- py: A supplement to the ESTRO/EAU/EORTC recommendations on prostate Brachytherapy. Radiother Oncol 2007; 83: 3-10. 32. Orio PF 3rd1, Merrick GS, Grimm P, Blasko J, Sylvester J, Allen ZA, Butler WM, Chaudhry UU. Effects of the time interval between prostate brachytherapy and postimplant dosimetric evaluation in community practice: analysis of the Pro- Qura database Am J Clin Oncol. 2008 Dec;31(6):523-31 33. Nath R, Bice W, Butler W, Chen Z, Meigooni A, Narayana V, Rivard M, Yu Y. AAPM recommendations on dose prescription and reporting methods for per- manent interstitial brachytherapy for prostate cancer: The report of Task Group 137. Med. Phys. 2009 Vol. 36: 11, 5310-5322. 34. Sievert FA, Brabandere M, Kiritsis C, Kovács G, Venselaar J. Phantom inves- tigations on CT seed imaging for interstitial brachytherapy. Radiother Oncol 2007; 85: 316-323. 35. Kälkner KM, Lundell M, Levitt S, Nilsson S. Prostate displacement kit: Reduc- ing the radiation dose to the rectum. Radiother Oncol 2006; 81: 291-293. 36. Milickovic, N., Mavroidis, P., Tselis, N., Nikolova, I., Katsilieri, Z., Kefala, V., Zamboglou, N., Baltas, D. 4D analysis of influence of patient movement and anatomy alteration on the quality of 3D U/S-based prostate HDR brachythera- py treatment delivery. Med Phys, 38 (9): 4982-4993, 2011. 37. Langley S, Ahmed HU, Al-QaisiehB, et al . Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int 2012; 109 (Suppl. 1):7–16. 38. Klotz, L. & Emberton, M. Management of low risk prostate cancer —active surveillance and focal therapy, Nat. Rev. Clin. Oncol. 11, 324–334 (2014); pub- lished online 13 May 2014; doi:10.1038/nrclinonc.2014.73 39. De la Rosette J, Ahmed H, Barentsz J, et al . Focal therapy in prostate cancer– report from a consensus panel. J Endourol 2010; 24:775–780. 40. van den Bos W, et al . Focal Therapy in Prostate Cancer: International Multi- disciplinary Consensus on Trial Design. Eur Urol (2014), http://dx.doi. org/10.1016/j.eururo.2014.01.001 41. Taira AV, Merrick GS, Butler WM, Galbreath RW, Lief J, Adamovich E, Wallner KE. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1336-42 42. Henry AM, Al-Qaisieh B, Gould K, Bownes P, Smith J, Carey B, Bottomley D, Ash D. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):50-6. 43. Hinnen KA, Battermann JJ, van Roermund JG, Moerland MA, Jürgen- liemk-Schulz IM, Frank SJ, van Vulpen M. Long-term biochemical and surviv- al outcome of 921 patients treated with I-125 permanent prostate brachythera- py. Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1433-8. 44. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Fearn PA, Kattan MW, Stock RG. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1472-7. 45. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institu- tional analysis of long-term outcome for stages T1-T2 prostate cancer treat- ed with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):327-33. 46. Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, Mullen E. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005 May;173(5):1562-6. 47. Sylvester JE, Grimm PD, Blasko J, Millar J, et al . 15 year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external

beam radiotherapy and brachytherapy:Seattle experience. Int J Radiat Oncol Biol Physics 2007; 67: 57-64, 48. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Ku- pelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupBJU Int. 2012 Feb;109 Suppl 1:22-9. 49. Horwitz EM, Levy LB, Thames HD,et al. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer pa- tients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis Cancer. 2006 Oct 1;107(7):1496-502 50. Toledano A, Chauveinc L, Flam T, et al .PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup Brachytherapy. 2006 Apr-Jun;5(2):122-6 51. Stock RG, Stone NN, Cesaretti JA, Rosenstein BS.et al. Biologicaly effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment bi- opsy results. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):527-33 52. Ash D, Al-Qaisieh B, Bottomley D, Carey B, Joseph J. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer Radiother Oncol. 2006 May;79(2):185-9 53. Burri RJ1, Ho AY, Forsythe K, Cesaretti JA, Stone NN, Stock RG. Young men have equivalent biochemical outcomes compared with older men after treat- ment with brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1315-21 54. Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Adamovich E Obesity is not predictive of overall survival following permanent prostate brachytherapy Am J Clin Oncol. 2007 Dec;30(6):588-96 55. Stock RG, Cahlen O, Cesaretti JA Kollmeier M, Stone N, Combined modality treatment in the management of high risk prostate cancer. Int J Radiat Oncol Biol Physics 2004; 59: 1352-1359 56. Dattoli M, Wallner K, True L, Cash J, Sorace R, Long-term outcomes after treat- ment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high risk features. Cancer 2007; 110: 551-555 57. Koontz BF, Chino J, Lee WR, Hahn CA et al . Morbidity and prostate-spe- cific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer Brachytherapy 2009; 8: 191-196 58. Pellizon AC, Nadalin W, Salvajoli AC et al . Results of high dose rate afterload- ing brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiother. Oncol;2006: 33: 167- 172 59. Vargas CE, Martinez AA, Boike TP, et al . High-dose irradiationfor prostate cancer via a high-dose-rate brachytherapy boost: Results of a phase I to II study. Int J RadiatOncolBiolPhys 2006;66:416-423. 60. Phan TP, Syed AM, Puthawala A, et al . High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 2007; 177:123-127 61. Kalkner KM, Wahlgren T, Ryberg M, et al . Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: A 6-year follow-up. ActaOncol 2007;46:909- 917. 62. Demanes DJ, Brandt D, Schour L, et al . Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by an- drogen deprivation. Am J ClinOncol 2009;32: 342-347 63. Zwahlen DR, Andreonopoulos N, Matheson B et al . High dose rate rbachyther- apy in combination with conformal external beam radiotherapy in the treat- ment of prostate cancer. Brachytherapy 2010; 9: 27-35 64. Wilder RB, Barme GA, Gilbert RF, et al . Preliminary results in prostate cancer patients treated with high-dose-rate brachytherapy and intensity modulated radiation therapy (IMRT) vs. IMRT alone. Brachytherapy 2010;9:341-348 65. Kaprealian T, Weinberg V, Speight JL et al . High dose rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes. Int J RadiatOncolBiolPhys 2012; 82: 222-227 66. Martinez AA, Gonzalez J, Ye H et al . Dose escalation improves cancer related